IL17A and tuberculosis: It is noteworthy that while IL‐17 inhibitors had a good safety profile in short‐term clinical trials,13 in the present study, two patients were tested positive for tuberculosis and detected with hepatitis B virus replication during use of IL‐17 inhibitors; therefore, in using IL‐17 inhibitors, clinicians are expected to exercise greater vigilance and strictly follow the guidelines to regularly follow up the infection indicators, so as to minimize the development of adverse reactions/events.